Early Dapagliflozin in Non-Diabetic Acute Myocardial Infarction Patients Post-PCI: Effects on Cardiovascular Outcomes and Left Ventricular Remodeling
Early dapagliflozin in non-diabetic AMI patients did not reduce 6-month MACE but significantly improved LV function and remodeling, suggesting cardioprotective benefits beyond glycemic control, especially in high-risk subgroups.
Authors
- Mohamed Elsayed Zahran (ORCID: https://orcid.org/0000-0001-6843-1374)
- Hazem Salama Emad Salem (ORCID: https://orcid.org/0000-0001-5077-0757)
- Islam Bastawy (ORCID: https://orcid.org/0000-0003-2838-7633)
- Ramzy Mohamed El-Mawardy
- Abdelrahman Attia
- M.F. Aziz
Institutions
- Ain Shams University (EG)
Publication Details
- Journal
- Journal of the Saudi Heart Association
- Published
- 2025-11-12
- DOI
- https://doi.org/10.37616/2212-5043.1464
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00